<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03380468</url>
  </required_header>
  <id_info>
    <org_study_id>Stage-1</org_study_id>
    <nct_id>NCT03380468</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma</brief_title>
  <acronym>ACTPI</acronym>
  <official_title>Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Solid subtype, micropapillary subtype, vascular involvement, pleural involvement and low
      differentiation are high risk factors of post-operative recurrence for early-stage lung
      adenocarcinoma patients. The purpose of this clinical trial is to determine whether the
      widely used adjuvant chemotherapy strategy cisplatin/ pemetrexed is more effective than no
      further treatment for Stage pI lung adenocarcinoma patients with high post-operative
      recurrence risk - in terms of no dose related toxicities, premature treatment withdrawal or
      death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Management of lung cancer varies according to the clinical and pathological stage. For stage
      I lung adenocarcinoma, radical surgery is the preferred initial treatment and adjuvant
      chemotherapy is usually not recommended due to a fine prognosis and relatively low
      post-operative recurrence rate. Still, a number of stage pI patients will suffer a relapse
      after surgery, among which are highly associated with solid subtype, micropapillary subtype,
      vascular involvement, pleural involvement and low differentiation. Recently, some
      retrospective researches have shown a significant survival benefit of adjuvant chemotherapy
      for such stage pI high-recurrent-risk patients, but there lacks evidence from prospective
      randomized clinical trails.

      Objective:

        1. Major: to compare disease free survival and over all survival of fully resected stage pI
           high-recurrent-risk patients from both arms (adjuvant chemotherapy vs. observation)

        2. To assess the safety and efficacy of chemotherapy regimen cisplatin plus pemetrexed to
           fully resected stage pI high-recurrent-risk patients.

        3. To collect clinical pathological characteristics and prognosis information of stage pI
           patients with solid subtype, micropapillary subtype, vascular involvement, pleural
           involvement and low differentiation.

        4. To determine the association among age, gender, smoking history, pathological subtypes,
           histological differentiation, pleural involvement, vascular involvement and driving
           mutations.

      Randomization:

      Each of the patients enrolled will be recorded in the computer system. Blank randomization
      will be done using a digital randomization software, at least 1 week before the first time of
      chemotherapy or observation.

      Prechemotherapy assessment: For all the patients enrolled, the postoperative physical or
      laboratory examination should be equally qualified no matter which group they will be in. For
      Group Adjuvant Chemotherapy patients, they will receive laboratory examinations before
      chemotherapy to test blood cells and liver function in consideration of safety as routine.

      Follow up:

      Patients will be followed up per 4 months for the first three years and each six months for
      the forth to fifth years during the research. Lung multi-detector row computed tomography
      (MDCT) and abdominal ultrasonography tests will be done twice a year; bone SPECT scan and
      enhanced brain MRI scan will be conducted per year routinely. Patients will be suggested to
      continue the annual follow-up after the research.

      Main research variables:

      Primary end point: Disease free survival in the two arms

      Secondary endpoints:

        1. Overall survival

        2. Recurrence pattern: Locoregional recurrence, metastatic recurrence, or both

        3. Quality of life: assessed with Eastern Cooperative Oncology Group- quality of life
           questionnaire(EORTC QLQ-C30/- LC13) scale.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence free survival (RFS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>from date of randomization until the date of showing signs of relapse, including evidence of medical image or pathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>from date of randomization until the date of death from any cause, withdrawal of consent, or the end of the study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recurrence pattern</measure>
    <time_frame>up to 5 years</time_frame>
    <description>locoregional recurrence, metastatic recurrence, or both.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 5 years</time_frame>
    <description>assessed with Eastern Cooperative Oncology Group-quality of life questionnaire(EORTC QLQ-C30/- LC13) scale.
Discription of EORTC QLQ-C30/- LC13:
The full name of the scale is Eastern Cooperative Oncology Group- quality of life questionnaire, including a core scale (EORTC QLQ-C30, version 3.0) and a module specified for lung cancer (EORTC QLQ- LC13). The scale is authorized by Quality of Life Department, EORTC Headquarters (Avenue E Mounier 83 - B11, 1200 Brussels BELGIUM) for scientific research.
The scale ranges in score from 0 to 100. A higher score represents a a better health status.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cisplatin plus pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: cisplatin 75mg/m2 iv Drug: pemetrexed 500mg/m2 iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation and follow up only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin plus pemetrexed</intervention_name>
    <description>cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv</description>
    <arm_group_label>Cisplatin plus pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stage pI lung adenocarcinoma confirmed through formalin-fixed paraffin-embedded tumor
             tissue, complete resection with mediastinal lymph node dissection

          2. Meet one of following conditions: a, Solid predominant adenocarcinomas; b,
             micropapillary predominant adenocarcinoma; c, low differentiation, unable to identify
             histological subtypes; d, pleural involvement; e, vascular involvement with solid
             subtype component or micropapillary component.

          3. Aged 18-70 years old.

          4. Eastern Cooperative Oncology Group score standard (ECOG) status 0-1.

          5. Medical condition permits adjuvant chemotherapy.

          6. Patients accept the clinical trial protocol and Informed Consent Form (ICF) signed.

        Exclusion Criteria:

          1. Concurrent other malignancies

          2. Prior chemotherapy and/or radiation therapy for lung cancer

          3. Central type lung cancer

          4. Concurrent other unresected suspicious nodules or masses in lung

          5. Medical condition that will not permit treatment or follow up according to the
             protocol, or ECOG status &gt;1.

          6. Pregnant or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haiquan Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haiquan Chen, MD</last_name>
    <phone>+86-21 64175590</phone>
    <phone_ext>1707</phone_ext>
    <email>hqchen1@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Haiquan, MD</last_name>
      <phone>+86-21 64175590</phone>
      <phone_ext>1707</phone_ext>
      <email>hqchen1@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D'Amico TA, Boyd JA. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009 Nov 15;115(22):5218-27. doi: 10.1002/cncr.24625.</citation>
    <PMID>19672942</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Li J, Wang R, Li Y, Pan Y, Cai D, Hu H, Li H, Ye T, Luo X, Zhang Y, Li B, Shen L, Sun Y, Chen H. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Sci Rep. 2014 Nov 24;4:7163. doi: 10.1038/srep07163.</citation>
    <PMID>25418354</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Wang R, Cai D, Li Y, Pan Y, Hu H, Wang L, Li H, Ye T, Luo X, Zhang Y, Li B, Shen L, Sun Y, Chen H. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thorac Oncol. 2014 Dec;9(12):1772-8. doi: 10.1097/JTO.0000000000000341.</citation>
    <PMID>25226429</PMID>
  </reference>
  <reference>
    <citation>Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011 May;24(5):653-64. doi: 10.1038/modpathol.2010.232. Epub 2011 Jan 21.</citation>
    <PMID>21252858</PMID>
  </reference>
  <reference>
    <citation>Shimada Y, Saji H, Yoshida K, Kakihana M, Honda H, Nomura M, Usuda J, Kajiwara N, Ohira T, Ikeda N. Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection. J Thorac Oncol. 2012 Aug;7(8):1263-70. doi: 10.1097/JTO.0b013e31825cca6e.</citation>
    <PMID>22673056</PMID>
  </reference>
  <reference>
    <citation>Al-Alao BS, Gately K, Nicholson S, McGovern E, Young VK, O'Byrne KJ. Prognostic impact of vascular and lymphovascular invasion in early lung cancer. Asian Cardiovasc Thorac Ann. 2014 Jan;22(1):55-64. doi: 10.1177/0218492313478431. Epub 2013 Sep 4.</citation>
    <PMID>24585645</PMID>
  </reference>
  <reference>
    <citation>Chen YY, Huang TW, Tsai WC, Lin LF, Cheng JB, Lee SC, Chang H. Lymphovascular space invasion and tumor differentiation are predictors for postoperative recurrence in patients with pathological stage I nonsmall cell lung cancer. J Chin Med Assoc. 2014 Aug;77(8):416-21. doi: 10.1016/j.jcma.2014.05.008. Epub 2014 Jul 12.</citation>
    <PMID>25028298</PMID>
  </reference>
  <reference>
    <citation>Park C, Lee IJ, Jang SH, Lee JW. Factors affecting tumor recurrence after curative surgery for NSCLC: impacts of lymphovascular invasion on early tumor recurrence. J Thorac Dis. 2014 Oct;6(10):1420-8. doi: 10.3978/j.issn.2072-1439.2014.09.31.</citation>
    <PMID>25364519</PMID>
  </reference>
  <reference>
    <citation>Yano M, Sasaki H, Moriyama S, Kawano O, Hikosaka Y, Fujii Y. Prognostic factors of pathologic stage IB non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2011;17(1):58-62. Erratum in: Ann Thorac Cardiovasc Surg. 2011 Apr;17(2):215.</citation>
    <PMID>21587131</PMID>
  </reference>
  <reference>
    <citation>Huang H, Wang T, Hu B, Pan C. Visceral pleural invasion remains a size-independent prognostic factor in stage I non-small cell lung cancer. Ann Thorac Surg. 2015 Apr;99(4):1130-9. doi: 10.1016/j.athoracsur.2014.11.052. Epub 2015 Feb 20. Review.</citation>
    <PMID>25704861</PMID>
  </reference>
  <reference>
    <citation>Jiang L, Liang W, Shen J, Chen X, Shi X, He J, Yang C, He J. The impact of visceral pleural invasion in node-negative non-small cell lung cancer: a systematic review and meta-analysis. Chest. 2015 Oct;148(4):903-911. doi: 10.1378/chest.14-2765. Review.</citation>
    <PMID>25675151</PMID>
  </reference>
  <reference>
    <citation>Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao MS, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 1;28(1):29-34. doi: 10.1200/JCO.2009.24.0333. Epub 2009 Nov 23.</citation>
    <PMID>19933915</PMID>
  </reference>
  <reference>
    <citation>Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 1;26(31):5043-51. doi: 10.1200/JCO.2008.16.4855. Epub 2008 Sep 22.</citation>
    <PMID>18809614</PMID>
  </reference>
  <reference>
    <citation>Luo J, Huang Q, Wang R, Han B, Zhang J, Zhao H, Fang W, Luo Q, Yang J, Yang Y, Zhu L, Chen T, Cheng X, Wang Y, Zheng J, Wu H, Xia W, Chen H. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB. J Cancer Res Clin Oncol. 2016 Sep;142(9):2031-40. doi: 10.1007/s00432-016-2192-6. Epub 2016 Jul 5.</citation>
    <PMID>27379889</PMID>
  </reference>
  <reference>
    <citation>Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, Brambilla EM. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. J Clin Oncol. 2015 Oct 20;33(30):3439-46. doi: 10.1200/JCO.2014.58.8335. Epub 2015 Apr 27.</citation>
    <PMID>25918286</PMID>
  </reference>
  <reference>
    <citation>Liu CH, Peng YJ, Wang HH, Chen YC, Tsai CL, Chian CF, Huang TW. Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non-small cell lung cancer patients. Thorac Cancer. 2015 Sep;6(5):620-8. doi: 10.1111/1759-7714.12233. Epub 2015 Feb 27.</citation>
    <PMID>26445611</PMID>
  </reference>
  <reference>
    <citation>Park SY, Lee JG, Kim J, Byun GE, Bae MK, Lee CY, Kim DJ, Chung KY. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J Cardiothorac Surg. 2013 Jun 11;8:151. doi: 10.1186/1749-8090-8-151.</citation>
    <PMID>23759129</PMID>
  </reference>
  <reference>
    <citation>Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S, Honda S, Yamasaki N. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007 Jun;56(3):341-8. Epub 2007 Mar 9.</citation>
    <PMID>17350137</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Lu C, Lu Y, Yu B, Lv F, Zhu Z. The predictive and prognostic values of factors associated with visceral pleural involvement in resected lung adenocarcinomas. Onco Targets Ther. 2016 Apr 20;9:2337-48. doi: 10.2147/OTT.S100965. eCollection 2016.</citation>
    <PMID>27143929</PMID>
  </reference>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Haiquan Chen</investigator_full_name>
    <investigator_title>Chief,department of thoracic surgery, Fudan University Shanghai Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Lung adenocarcinoma</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

